Novo Nordisk's Decade Blueprint Meets a Doubting Market

Novo Nordisk targets DKK 150bn pipeline revenue by 2035, but 2026-2030 growth will only match peers; Deutsche Bank and Jefferies cut targets.

Novo Nordisk used its capital markets day to sketch the contours of its next ten years, but the reception on the trading floor was anything but celebratory. Management laid out ambitions to bring more than five multi-blockbuster medicines to market by 2030, alongside risk-adjusted pipeline revenue exceeding DKK 150 billion by 2035 — roughly USD 23 billion. Yet the same presentation tempered expectations for the near term, with the company guiding that revenue growth between 2026 and 2030 will merely track the broader industry peer group rather than outpace it.

That message landed hard. The stock closed at EUR 33.94 in the prior session and was trading at EUR 33.35 on the day, down 0.9%, extending a year-to-date decline of 24%. According to media reports, the investor day announcements had already triggered an intraday slide of as much as 9% on Monday.

Analysts Waste Little Time

By Tuesday, several research houses had adjusted their models. Deutsche Bank cut its price target to DKK 245 from DKK 265 while maintaining a "Sell" rating. Jefferies followed suit, trimming its target to DKK 275 from DKK 285 and keeping a "Hold" stance. The reasoning echoed a common concern: the capital markets day presentations failed to dispel lingering uncertainty ahead of semaglutide's patent expiry.

Novo Nordisk had stressed during the event that its balance sheet could absorb larger acquisitions, and that the DKK 150 billion target rests on internal, risk-adjusted assets with future deals excluded for now. Even so, investors and analysts pressed on the assumptions behind future pricing and the direction of M&A activity.

The Clinical Scorecard

Whether Novo Nordisk can defend its innovation lead in metabolic therapies against a strengthening field comes down to hard data, and the latest late-stage results for its lead candidate CagriSema provide the benchmark. In a Phase 3 trial involving diabetes patients, the compound achieved an estimated average weight loss of 12.4%. Company figures indicate that the 1 mg dose proved superior to Eli Lilly's tirzepatide at 5 mg in reducing weight. A separate late-stage study in adults with obesity showed 21% weight loss at a 1.0 mg dose compared with placebo.

Meanwhile, the strategic focus is shifting toward oral formulations. CEO Mike Doustdar told Reuters that oral obesity therapies could account for as much as half the global weight-loss drug market by 2030. Novo Nordisk already has five additional oral candidates in clinical development following the launch of its first weight-loss pill. How quickly those oral formulations reach approval readiness will directly determine how much market share the company can command in the coming decade.

Partnerships and a Possible NYSE Listing

The pipeline is being broadened through external alliances. Novo Nordisk signed a licensing and development agreement with Orbis Medicines worth up to USD 1.4 billion for oral cardiometabolic therapies, coupled with a strategic equity stake. On the operational side, the company is working with Anthropic to deploy advanced computational models in research workflows and software development. The system is already being used to automate clinical study report generation, cutting patient documentation timelines from several months to just minutes.

Structurally, management is also weighing changes for international investors. Doustdar hinted to the Financial Times that a direct listing on the New York Stock Exchange — replacing the current ADR structure — is conceivable, though not currently being pushed. Such a move could bolster US market liquidity over the longer term.

China Approval Offers a Counterpoint

Away from the strategic debates, Novo Nordisk notched a tangible operational win. As Reuters reported, Wegovy received approval in China on 10 September, becoming the first GLP-1 receptor agonist of its class there for treating metabolic dysfunction-associated steatohepatitis (MASH). Whether fresh regional approvals will be enough to ease medium-term growth concerns remains the pivotal question for the share price. The market is demanding clear answers on how the pharmaceutical group intends to offset the looming patent cliff on its key active ingredient.

Where the Risks Cluster

The bear case centers on the deceleration in expansion speed. By pegging growth for 2026 to 2030 at the level of industry peers, the company signals an end to its extraordinary run of outperformance. Competition in obesity and diabetes therapies is intensifying, with Eli Lilly countering with its own products while pharma companies worldwide attempt to break into the segment. Add to that the inherent risk of late-stage trials: delays or unexpected safety concerns in further CagriSema studies or the five oral projects would put the ambitious DKK 150 billion pipeline revenue target for 2035 in jeopardy.

The financial burden remains heavy, too. Novo Nordisk continues to commit USD 18 million for 2026 to 2030 in a partnership with UNICEF to prevent overweight in more than 80 million children across seven countries. Rising research spending combined with a slower growth trajectory carries the risk that margins come under pressure in the medium term.

What Investors Are Watching

Clear decision parameters are emerging. As long as the stock holds above its previous annual low, the pipeline valuation leaves room for a fundamental bottoming-out after the recent correction. If CagriSema's trial successes can be converted into swift regulatory filings and the oral candidates advance on schedule, confidence in the long-term growth targets for 2030 should return. Should sentiment sour instead — through approval setbacks or intensified price competition — the valuation discount could become entrenched. The wide gap to the 52-week high of EUR 54.86 illustrates how much faith the market has already withdrawn in recent months.

The next concrete catalyst for the stock is the release of further detailed Phase 3 analyses for CagriSema, along with specific milestones for the five oral candidates in the months ahead.